FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of May 2007
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosure:
FDA publishes documents
FDA publishes ACAM2000 Advisory Committee briefing documents and questions
Cambridge, UK and Cambridge, Massachusetts - 15 May 2007 - Acambis plc (Acambis)
(LSE: ACM) announces that the ACAM2000-related briefing documents for the
Vaccines and Related Biological Products Advisory Committee scheduled for
Thursday, 17 May are now accessible via the US Food and Drug Administration's
(FDA) website.
Briefing documents have been provided by the FDA and Acambis. The documents
include details of the safety and efficacy data generated by Acambis through its
clinical development programme.
This information can be accessed at http://www.fda.gov/ohrms/dockets/ac/07/
briefing/2007-4292B2-00-index.htm.
Acambis developed ACAM2000 under contracts with the US Centers for Disease
Control and Prevention in response to the US Government's need for a stockpile
of smallpox vaccine to counter the threat of smallpox being used as a biological
weapon. To date, Acambis has supplied 192.5 million doses of ACAM2000 to the US
's Strategic National Stockpile under an FDA Investigational New Drug
application.
-ends-
Enquiries:
Acambis plc
Ian Garland, Chief Executive Officer
Elizabeth Brown, Acting Chief Financial Officer
Lyndsay Wright, VP, Communications and IR
Tel: +44 (0) 1223 275 300
Brunswick
Jon Coles / Justine McIlroy / Margherita Lupi
Tel: +44 (0) 20 7404 5959
About Acambis
Acambis is a leading biotechnology company targeting infectious diseases with
novel vaccines. Acambis' development-stage pipeline includes vaccines that could
either offer improvements over existing products or target unmet medical needs.
ChimeriVax-JE, Acambis' most advanced product in the non-biodefence pipeline,
has to date shown an excellent safety and efficacy profile following pivotal
Phase 3 trials. It is currently undergoing paediatric trials in India and is
partnered with sanofi pasteur and Bharat Biotech. Acambis' proprietary
ChimeriVax technology, developed in association with St Louis University, has
also been used to develop ChimeriVax-West Nile, which is undergoing Phase 2
clinical testing, making it the most advanced investigational vaccine against
the West Nile virus. Acambis also has the only vaccine in development against
Clostridium difficile bacteria, a leading cause of hospital-acquired infections.
Recognised internationally as the leading producer of smallpox vaccines, Acambis
is developing an investigational smallpox vaccine, ACAM2000, and is
manufacturing emergency-use stockpiles of this investigational vaccine for the
US Government and other governments around the world.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). More information is available at
www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see relevant risk
sections in the Company's latest Annual Report and Form 20-F, in addition to
those detailed on the Company's website and in the Company's filings made with
the Securities and Exchange Commission from time to time. These forward-looking
statements are based on estimates and assumptions made by the management of
Acambis and are believed to be reasonable, though are inherently uncertain and
difficult to predict. Actual results or experience could differ materially from
the forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 15 May 2007 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: VP, Communications and IR.